New drug aims to save premature babies' eyesight
NCT ID NCT07093255
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new medicine called FLQ-101 in 18 premature babies born at 26-27 weeks who are at high risk for retinopathy of prematurity (ROP), an eye disease that can cause blindness. The main goal is to check if the drug is safe and how it works in the body. Researchers will monitor side effects and measure how the drug is processed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINOPATHY OF PREMATURITY (ROP) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
St. David's Medical Center
RECRUITINGAustin, Texas, 78705, United States
Contact Phone: •••-•••-••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single eye injection save sight in premature infants?
- Nasal fentanyl spray could ease painful eye exams for premature babies
- New study tests if videos can boost Parents' knowledge of preemie eye disease screening
- Cord blood transfusions could be safer for preterm babies
- Premature baby eye treatments under the microscope
- Massive study of 7,000 preemies aims to save sight